The latest: Genscript Biotech Corp. (1548.HK) announced on Sunday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) has sold 692,782 shares through a private placement to LGN Holdings Ltd., a subsidiary of Hillhouse Investment Management, for about $22.2 million.

Looking up: Legend will use the funds raised for general working capital and business expansion.

Take Note: Upon completion of the transaction, Genscript’s shareholding in Legend will be slightly diluted from 48.38% to 48.29%.

Digging Deeper: Legend is Genscript’s cellular therapeutics business subsidiary. After years of spending, Legend’s new Cilta-cel product, being commercialized by a joint venture with Johnson & Johnson’s (JNJ.US) Janssen Biotech, accumulated sales of $206 million in the year since it was approved by the U.S. Food and Drug Administration (FDA) in last year’s first quarter.

Market Reaction: Legend Biotech shares rose 1.2% to $69.73 in New York last Friday, and trade near their 52-week high. Genscript shares fluctuated narrowly during the Monday morning session in Hong Kong and closed down 1.2% at HK$19.48. The stock now trades near the lower end of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

111 Inc reports first ever opertaing profit

Inaugural operating profit fails to lift 111 Inc.

The drug distributor expects to benefit from an ongoing crackdown on corruption in its industry due to the company’s focus on distribution to pharmacies rather than hospitals Key Takeaways: 111…